Related Experiment Video
Updated: Jul 31, 2025

06:05
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
Published on: February 19, 2021
1.3K
How to phase II: Timelines, perceptions, and suggestions from PGY-1 residency program directors.
Summary
Phase II of pharmacy residency matching offers a structured process but needs timeline standardization. Improvements in application management and technical aspects are suggested for better applicant and program experiences.
Area of Science:
- Pharmacy Education
- Residency Matching
- Graduate Medical Education
Background:
- Phase II was established in 2016 to structure interactions between pharmacy residency applicants and programs with unfilled positions.
- Existing literature offers guidance, but clarity is needed on navigating Phase II for successful matches.
- Continuous evaluation of Phase II is necessary given its operation for over six years.
Purpose of the Study:
- To describe the structure and timelines of Phase II for pharmacy residency programs.
- To assess program personnel demand within Phase II.
- To gather perceptions and suggestions from Residency Program Directors (RPDs) to enhance Phase II for all stakeholders.
Main Methods:
- A 31-item survey was distributed to PGY-1 RPDs participating in Phase II in June 2021 and May 2022.
- The survey included demographic, timeline-specific, interview screening, and qualitative questions.
- Reminders were sent weekly, achieving a 37.2% response rate (180 out of 484 RPDs).
Main Results:
- Participating programs averaged 1.4 open Phase II positions with 31 applicants per position.
- Significant variability was observed in application screening, applicant contact, and interview timelines.
- RPDs valued the structured process and applicant quality but cited challenges with application volume, review time, and technical issues.
Conclusions:
- Phase II represents an improvement over previous matching methods, offering a more structured approach.
- Variability in program timelines persists, indicating a need for refinement.
- Respondents suggested extending the Phase II timeline, implementing a universal application deadline, and improving technical aspects.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Assessment of the Gastrointestinal System II: Health Perception Pattern
149
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health Perception Patterns
Health perception patterns offer valuable insights into a patient's lifestyle habits and how they may impact their GI health. These patterns include:
Health Perception Patterns
Health perception patterns offer valuable insights into a patient's lifestyle habits and how they may impact their GI health. These patterns include:
149
Preclinical Development: Overview
4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Drug Administration and Therapy Phases: Overview
589
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
589
Phase II Reactions: Glucuronidation
580
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
580
Methods of Documentation II: POMR
1.0K
The Problem-Oriented Medical Record (POMR) revolutionized medical record-keeping by introducing a systematic approach focusing on the patient's problems rather than merely listing symptoms. Dr. Lawrence Weed's introduction of this method in the 1960s marked a significant advancement in medical documentation. The POMR framework consists of four key components: the database, problem list, plan of care, and progress notes.
1.0K

